JERUSALEM, November 9, 2016 /PRNewswire/ --
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage
biopharmaceutical company focused on developing drugs based on its
proprietary Accordion Pill platform technology, announces that the
Company will be hosting an investigator meeting on November 11-12, 2016 in Barcelona.
The investigator meeting will bring together more than 200
leading Parkinson's disease clinicians, care providers and clinical
research coordinators.
These leading clinicians represent current and prospective
clinical trial sites in the pivotal, Phase III clinical trial of
the Company's Accordion Pill Carbidopa/Levodopa (AP-CD/LD), the
Accordance Study, for the treatment of the symptoms of Parkinson's
disease (PD) in advanced PD patients.
The Accordance study is a multicenter, randomized, double-blind,
double-dummy, parallel, active-controlled Phase III trial in
the United States, Europe and Israel. The study is now expected to enroll
approximately 328 participants by the fourth quarter of 2017.
"The upcoming investigator meeting has been received with strong
interest and we appreciate attendees taking time from their busy
schedules to take part in this important two day event. This is one
of the official investigators meetings during the phase III study.
This meeting is especially timely as it follows on a recent
protocol amendment to the Accordance Study in which we reduced the
number of subjects from 460 to 328 subjects, without altering the
primary endpoint, study objectives or 90% powering of the study.
We look forward to what we expect will be an exceptional
event centered on advancing AP-CD/LD to the benefit of PD patients
worldwide," stated Zeev Weiss, CEO
of Intec Pharma.
About Intec Pharma Ltd.
Intec Pharma Ltd. is a clinical stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline currently includes three product
candidates in clinical trial stages: Accordion Pill
Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the
treatment of Parkinson's disease symptoms in advanced Parkinson's
disease patients, currently in Phase III, Accordion Pill Zaleplon,
or AP-ZP, which is being developed for the treatment of insomnia,
including sleep induction and sleep maintenance, and an Accordion
Pill that is being developed for the prevention and treatment of
gastroduodenal and small bowel ulcers induced by Nonsteroidal
Anti-Inflammatory Drugs. In addition, an Accordion Pill for
cannabinoid therapies (AP-CBD/THC) will enter Phase I clinical
trial in the first quarter of 2017.
Forward-Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe," "expect," "intend," "plan," "may," "should,"
"could," "might," "seek," "target," "will," "project," "forecast,"
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company's control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in
the company's filings with the Securities and Exchange Commission,
and include the following: the company's ability to develop and
commercialize its product candidates and obtain additional
financing necessary therefor; the length, cost and uncertain
results of the company's clinical trials; the potential of adverse
side effects or other safety risks that could preclude the approval
of the company's drug candidates; the availability of reimbursement
from government authorities and health insurance companies for the
company's products; the impact of product liability lawsuits; and
the influence of extensive and costly government regulation.
CONTACT INFORMATION
Zeev Weiss
Chief Executive Officer
+972(2)586-4657
Zeev@intecpharma.com
Anne Marie Fields
Senior Vice President
LHA
+1-212-838-3777
afields@lhai.com
SOURCE Intec Pharma Ltd.